36種藥品納入醫保藥品目錄 平均價格降幅達44%

The prices of 36 expensive drugs - half of them for cancer treatment - are now covered by medical insurance, after the authorities negotiated substantial price reductions.

在有關部門通過談判實現大幅降價後，36種高價藥現已納入醫保報銷範圍，其中半數是癌症治療藥物。

The Ministry of Human Resources and Social Security negotiated with pharmaceutical manufacturers on 44 drugs and managed to cut prices of 36 of them to be acceptable for coverage by the medical insurance fund, Xu Yanjun, a fund management official at the ministry, said at a news conference.

日前，人力資源和社會保障部的基金管理官員徐延君在新聞發佈會上表示，人社部與製藥企業就44種藥品進行了談判，成功將其中36種藥品的價格降至醫保基金報銷可接受的水平。

Compared with retail prices last year, prices of these drugs have decreased by 44% on average, he said.

徐延君稱，與去年的零售價相比，這些藥物的價格平均下降了44%。

padding-bottom: 70.67%;">

Five of the drugs are traditional Chinese medicines and 22 are imported Western medicines.

在這些藥品中，其中5種是中藥，22種是進口的西方藥物。

Prices of the drugs may be adjusted further when the contracts between the government and the manufacturers expire at the end of 2019, said Yan Qinghui, the ministry's deputy director of medical insurance.

人社部醫保司副司長顏清輝表示，政府與藥企簽訂的協議將於2019年底到期，屆時這些藥品的價格可能會作進一步調整。

"We hoped we could make full use of the advantages of the fund's group purchasing to include more drugs in the medical insurance directory," Yan said.

顏清輝說道：“我們希望我們能充分利用基金組織購買的優勢，在醫療保險目錄中加入更多的藥物。”